Memorial Sloan Kettering Cancer Center
ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement
By
ASCO 2022 Conference Coverage
FEATURING
Ghassan Abou-Alfa
By
ASCO 2022 Conference Coverage
FEATURING
Ghassan Abou-Alfa
Login to view comments.
Click here to Login